Reflections & Learnings from 2025

Executive Summary

The biotechnology sector in 2025 reached a critical inflection point. Following the capital abundance of 2020–2021 and the subsequent correction through 2024, the industry has entered a phase of recalibration defined by capital discipline and the operational integration of artificial intelligence (AI), amongst other variables. 2025 was a year of reset; global biotech financing remained constrained compared to previous peaks, forcing companies to prioritise fundamentals and efficiency over speculative growth.

Funding remained concentrated at the top. Venture funding for biotech rebounded by 70.9% in Q3 2025, reaching $3.1 billion, but late-stage assets and experienced teams captured most of the capital. M&A activity surged to ~$70 billion by October 2025, nearly doubling the prior year’s total, as acquirers targeted marketed or Phase III candidates. Simultaneously, AI transitioned from an experimental dark art to core operational infrastructure, with an estimated 30% of new drugs incorporating AI in discovery.

Leadership has evolved to meet demands. Boards are increasingly favouring executives who can combine scientific and commercial depth. Technical roles, similarly, are changing, with a high premium placed on 'purple' talent. These are professionals fluent in both wet-lab biology and dry-lab data science. Looking into 2026, companies that succeed will focus on disciplined growth, practical use of AI, and resilience in a complex geopolitical environment, particularly regarding the rise of China and the implications of the US BIOSECURE Act.

Introduction

The year 2025 serves as a juncture for the biotechnology industry. Following the exuberance and subsequent sugar rush of the pandemic era, the sector has entered a ten-year cycle focused on building more serious businesses. This dossier, produced by our team here at Mazards, and the trends we’ve examined over 2025, examines the state of the sector as it transitions into 2026.

The industry is moving away from 'growth at any cost' to asset-focused models and demonstrable clinical utility. This transition requires a great change in how capital is deployed and how pipelines are managed. Not to mention, how talent is recruited. 

By synthesising investment signals, leadership transitions, and technological trends, our analysis provides a plan for the leaders who can run both science and business with equal fluency - a new archetype of biotech leadership to handle high ambiguity as well as remain fiscally strict.

Biotech in 2025

1.1 Capital Discipline and the Two-Speed Market

The biotech funding environment in 2025 revealed a transitioning market. While venture funding increased significantly in Q3, rising from $1.8 billion in Q2 to $3.1 billion, this growth concealed structural bifurcation. At the upper tier, established venture firms successfully raised substantial vehicles - such as OrbiMed's $1.86 billion fund and Frazier Healthcare Partners' $1.3 billion fund. Average deal sizes for venture capital increased 54% to $18 million, but the number of startups receiving funding actually decreased, indicating capital concentration in later-stage growth investments.

Mid-level companies and those in the life science tools sector have struggled due to market fragmentation. For growth equity investors, a significant gap in investability has shown itself: many companies have revenues between $1 million and $6 million, while established growth investors often have a minimum investment criterion of $100 million. Interestingly, there was a strategic shift towards earlier-stage seed and Series A investments, where there is a conducive, uncomplicated cap table. 

1.2 M&A Resurgence and Strategic Precision

By October 2025, biopharma M&A reached ~$70 billion, a material departure from the cautious 2024. Strategic precision defined these deals; acquirers prioritised de-risked Phase III or marketed assets over broad platform exploration. Significant transactions included:

• Johnson & Johnson’s $14.6 billion acquisition of Intra-Cellular Therapies, securing validated CNS and neuroscience assets.

• Novartis’s $12 billion purchase of Avidity, providing rights to a neuromuscular Antibody Oligonucleotide Conjugate platform.

• AstraZeneca’s $1 billion acquisition of EsoBiotec, targeting in vivo CAR-T therapies.

1.3 Portfolio Prioritisation and Evidence-Based Triage

Organisations are aggressively pruning non-core programmes to extend cash runways for their most promising clinical candidates. Leading biopharmas are now terminating approximately 50% of discontinued assets in Phase I to avoid the high costs of registrational trials for low-potential molecules. AstraZeneca’s '5Rx' framework (Right Target, Right Tissue, Right Safety, Right Patient, Right Commercial Potential) exemplifies this trend, having achieved a five-fold increase in the proportion of molecules advancing from preclinical stages to Phase III completion.

Leadership Competencies Emerging in 2025

The successful biotech leadership profile has undergone a fundamental evolution. The visionary promoter is being replaced by the 'operator' who delivers big under constraint.

2.1 Dual-Fluency: Science and P&L

Boards now prioritise leaders who understand the science deeply while managing the business effectively. Investors demand C-suite leaders who can ‘go deep’ on the mechanism of action (MoA) without needing a translator, while simultaneously managing a complex P&L. This has led to the rise of the 'Physician-CEO' as well as the 'CSO-turned-CEO'.

2.2 Competency in Storytelling

In a market where 82% of investors state that a company’s clarity of vision informs their decisions, the ability to tell a clear story with data has become a differentiator. Leaders must weave complex scientific data into a compelling commercial equity story suitable for private equity (PE) diligence and partner engagement.

2.3 Evidence-Based Decision-Making

High-performing executives are recognised for making tough calls to terminate underperforming programmes early on. And by utilising predictive biomarkers, several mid-cap biotechs successfully saved millions in capital in 2025 by terminating Phase II programmes early and redirecting funds to higher-probability assets.

2.4 Lean Team Design

Operators capable in both science and business make organisations adaptable. Instead of headcount growth being a proxy for success, leaders are assembling small, cross-functional teams of 'athletes' - individuals who are multi-skilled and who can wear multiple hats to maintain velocity without layering management.

AI With Heart

In 2025, AI shifted from hype to practical daily operations. Companies are using it to support discovery, manufacturing, regulatory tasks, among others.

3.1 From Hype to Infrastructure

The focus has shifted from acquiring flashy algorithms to building robust 'Data Ops' infrastructure. Companies have realised that clean, annotated, multimodal biological data is the true scarcity and the primary moat for value creation. An estimated 95% of pharma companies are now investing in AI, with 87% of recent alliances focused on AI-enabled R&D platforms.

3.2 A Human-in-the-Loop Requirement

Despite AI’s predictive power, regulators (FDA/EMA) still require explainability. AI excels at pattern recognition, but human judgement remains essential for ethical trial design, interpreting safety signals, and making the creative leaps required for breakthroughs. In practice, human experts still need to review and guide decisions.

3.3 Governance and IP Risks

2025 saw the first major legal skirmishes regarding IP ownership of AI-generated assets. In response, companies are implementing strict internal ethics panels and data governance frameworks to manage the risks of biased datasets and ensure that AI-assisted discoveries are patentable.

High-Impact AI Use Cases

Verifiable evidence from 2024–2025 highlights specific areas where AI is delivering quantifiable ROI:

• Target Identification and Drug Discovery: Insilico Medicine used its AI platform to identify a novel fibrosis target and generate a lead candidate in under 18 months, one-third of the typical timeline, at roughly 10% of the normal cost.

• Patient Stratification: Machine learning models were used to retrospectively rescue the 'failed' AMARANTH Alzheimer's trial. By identifying a 'slow-progressor' subgroup, AI revealed that the drug actually slowed cognitive decline by 46% in that specific population.

• Adaptive Trial Design: 'Digital twin' technology and synthetic control arms are being used to model trial outcomes before enrolment. One collaboration showed that digital twins could reduce required placebo groups by up to 33% in Phase III Alzheimer’s trials.

• Manufacturing and CMC: AI-driven bioreactor process optimisation has achieved 15% increases in production yields for sterile injectables. In CGT manufacturing, AI vision systems have reduced batch failure rates from ~15% to <5%.

• Regulatory Documentation: Large Language Models (LLMs) are being used to draft Clinical Study Reports (CSRs) and safety narratives, reducing the 'first draft' time for standard regulatory documents by 60%.

Jobs & Talent for Executives and Scientists in 2026

The talent market has moved from broad growth hiring to carefully selecting highly capable individuals.

4.1 Macro Talent Trends

Headcount growth is no longer a proxy for success. Job postings in late 2024 and early 2025 fell by 20-30% year-on-year across major hubs, even as the pool of job seekers grew due to over 26,000 industry layoffs. Organisations are now hiring fewer people but paying premiums for multi-skilled 'athletes'.

4.2 Executive Expectations

Boards are increasingly replacing founder-CEOs with executives experienced in managing investors and keeping operations disciplined. There is a rising demand for operational CFOs who can span finance, strategy, business development, and more. Cross-functional fluency is now a prerequisite; a Chief Scientific Officer (CSO) is expected to understand FDA/EMA systems, and a VP of Research must have regulatory experience.

4.3 The Rise of 'Purple' Scientists

At the technical level, traditional bench science roles are evolving into hybrid roles. There is a massive shortage of purple scientists, individuals who sit at the intersection of 'wet lab' biology and 'dry lab' computational science. These scientists are expected to spend their mornings at the lab bench and their afternoons writing Python scripts to analyse their results.

4.4 Skills for the 2026 Market

To remain competitive, candidates must demonstrate:

• AI Literacy: Comfort using AI tools for productivity and decision support.

• Ambiguity Tolerance: The ability to maintain focus in 'survival mode' or resource-lean environments.

• Commercial Awareness: Scientists are now expected to understand the target product profile and the regulatory pathway.

PESTLE Analysis (2025–2026)

Political

Geopolitical tensions, particularly US-China relations, are changing the sector’s supply chains. The proposed BIOSECURE Act has created a rift across the supply chain, forcing Western firms to adopt 'China Plus One' manufacturing strategies. In the UK, the government is implementing the O’Shaughnessy Review to speed up trials, targeting approval times of under 150 days.

Economic

Capital remains selective and expensive. Higher interest rates have fundamentally altered financing, moving the industry into a 10-year cycle of seriousness about making profit-generating businesses. This has resurged alternative financing, such as royalty deals, which are projected to provide $14 billion in 2024.

Social

There is a growing mandate for clinical trial diversity and inclusion. The US FDA now requires diversity action plans for pivotal trials, and public scrutiny is increasing for companies that fail to meet these targets. Patient advocacy groups are becoming early stakeholders in the R&D process.

Technological

Beyond AI, 'Lab 4.0' (automation and IoT sensors) is becoming standard. Next-gen gene editing techniques (base/prime editors) are moving into common diseases. However, the increased digitisation of health data has made cybersecurity a major technological risk, following several high-profile ransomware attacks on CROs.

Legal

The legal environment is tightening with the impending EU AI Act, which classifies medical AI systems as high-risk and mandates transparency and risk management. In the US, the Inflation Reduction Act (IRA) is incentivising companies to pivot pipelines toward biologics, which receive a longer exemption from price negotiations compared to small molecules.

Environmental

ESG (Environmental, Social, and Governance) is no longer just nice to have. Big pharma partners are auditing biotech supply chains for carbon footprints. This is driving the adoption of greener chemistry and the move toward recyclable single-use bioreactors.

China’s Ascent Continues

5.1 First-in-Class

China’s biotech ascent is the result of sustained state industrial policy, including the 14th Five-Year Plan. For the first time, in 2024, the value of China’s out-licensing deals (assets sold to the West) exceeded the value of in-licensing deals. Major pharma firms are now sourcing a growing portion of their external pipelines from China-origin assets. 

5.2 The 'Sea Turtle' Dividend

The leadership of top Chinese biotechs (for example: BeiGene, Legend Biotech) is dominated by 'Sea Turtles', or Chinese scientists who trained at Western firms like Pfizer or Merck and then returned home. A secondary wave of mid-level technical talent (computational biologists and process engineers) is now returning, driven by US visa uncertainties.

5.3 Clinical and AI Velocity

China can recruit patient cohorts ~4x faster than US/EU counterparts due to its massive population and concentrated life science clusters. In AI, firms like XtalPi have successfully industrialised the interface between AI algorithms and robotic wet labs, creating dry-lab-to-wet-lab feedback loops that are amongst the most globally efficient.

5.4 Strategic Bifurcation

Despite this rise, China faces severe headwinds from the US BIOSECURE Act. This has caused a decoupling, where Western firms are diversifying into India and Singapore while Chinese firms are forced to out-license assets to the West at attractive valuations to extend cash runways.

What 2026 Will Demand from Biotech Leaders

Success in 2026 will depend on team strength rather than sheer size.

1. Disciplined Growth: Leaders must apply the fiscal discipline that was learned in 2025 to daily decisions. This means scaling infrastructure only in line with genuine milestones, rather than in anticipation of them.

2. AI-Enabled Decision-Making: 2026 leaders will use AI insights in daily decisions, moving beyond small experiments to integrating AI into core operations.

3. Dual Fluency: The siloed leader is already a relic. Success requires systems thinking mindsets where R&D, clinical, regulatory, and commercial plans are all unified and cohesive.

4. Organisational Resilience: Leaders must build elastic organisations that can reconfigure quickly as projects pivot. This requires an open, learning-oriented culture where teams feel safe to surface problems early.

5. Networked Leadership: Leaders must excel at building ecosystems. The ability to forge smart alliances (whether with big pharma, academia, or tech companies for AI expertise) will be crucial for weathering funding shortfalls.

Conclusion

The period of 2025-2026 is forging a more sober, disciplined, and technologically advanced biotech industry. The period of market adjustment was painful, resulting in thousands of layoffs and the closure of multiple firms, but it has yielded a sector focused on genuine value and clinical truth.

The companies that succeed in 2026 will be led by executives who can manage both science and business, making agile decisions. As the industry moves into this next phase, the divergence between those who adapted to 2025’s lessons and those who did not will widen in the coming years. For those who have sharpened their pipelines and embraced the pragmatic application of AI, the next biotech renaissance will hold immense opportunities.